SK Plasma said on the 25th it was selected as the technology export partner for Turkey's national strategic project to localize plasma-derived fractionation products.
On the 24th (local time) in Ankara, Turkey, the company signed a shareholders' agreement with the Turkish Red Crescent to build a plasma fractionation plant for the localization of nationally essential medicines and to establish a joint venture, ProTürk.
The deal was made during a summit between the two countries, with SK Plasma CEO Kim Seung-ju and Turkish Red Crescent President Fatma Meriç Yılmaz attending.
Under the agreement, SK Plasma will receive a technology transfer fee and secure 15% equity in ProTürk. The remaining 85% will be held by Kızılay Yatırım, an investment company under the Turkish Red Crescent, and Turkish government agencies.
ProTürk plans to build a production facility in the Çubuk area of Ankara capable of processing 600,000 liters of plasma annually. The facility will produce essential plasma-derived medicines such as albumin (ABM), which supplements proteins in the blood; immunoglobulin (IVIG), used to treat patients with immune deficiencies; and factor VIII (FVIII), a coagulation factor needed to treat bleeding disorders such as hemophilia A.
SK Plasma will transfer plasma fractionation manufacturing technology to ProTürk and receive technology fees in stages. The governments of both countries also plan to provide necessary administrative and policy support during the project, including help with approvals and securing a site.
Kim Seung-ju, CEO of SK Plasma, said, "Through collaboration with Turkey, we will build production infrastructure in a timely manner and seek additional opportunities in countries that need to localize essential medicines."